Critical Comparison: Antares Pharma (ATRS) & NuVasive (NUVA)
Antares Pharma (NASDAQ: ATRS) and NuVasive (NASDAQ:NUVA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitabiliy, risk, dividends, earnings, institutional ownership, analyst recommendations and valuation.
Insider & Institutional Ownership
31.7% of Antares Pharma shares are held by institutional investors. 11.6% of Antares Pharma shares are held by insiders. Comparatively, 4.7% of NuVasive shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This is a summary of current recommendations and price targets for Antares Pharma and NuVasive, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Antares Pharma currently has a consensus target price of $4.58, suggesting a potential upside of 59.41%. NuVasive has a consensus target price of $81.10, suggesting a potential upside of 26.96%. Given Antares Pharma’s stronger consensus rating and higher possible upside, research analysts plainly believe Antares Pharma is more favorable than NuVasive.
Earnings & Valuation
This table compares Antares Pharma and NuVasive’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Antares Pharma||$53.10 million||8.43||-$15.88 million||($0.12)||-23.92|
|NuVasive||$1.02 billion||3.18||$225.78 million||$0.62||103.03|
NuVasive has higher revenue and earnings than Antares Pharma. Antares Pharma is trading at a lower price-to-earnings ratio than NuVasive, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Antares Pharma has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500. Comparatively, NuVasive has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500.
This table compares Antares Pharma and NuVasive’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
NuVasive beats Antares Pharma on 8 of the 14 factors compared between the two stocks.
About Antares Pharma
Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges. The Company makes a reusable, needle-free spring action injection device, ZOMA-Jet or Twin-Jector, which is marketed through its partners for use with human growth hormone (hGH). The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies.
Nuvasive, Inc. is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process. Its principal product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The platform includes its software-driven nerve detection and avoidance systems, including NVM5, and intraoperative monitoring services and support; MaXcess, an integrated split-blade retractor system, and a range of implants and biologics. The platform combines three product categories: its MaXcess retractors, specialized implants and fixation products, and nerve monitoring systems and service offerings that collectively enable surgeons to detect and navigate around nerves, while directing customized access to the spine for implant delivery.
Receive News & Stock Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related stocks with our FREE daily email newsletter.